R&D | March 20, 2026
Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
The initial consideration for the transaction is US$ 12 million
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Subscribe To Our Newsletter & Stay Updated
